Enhertu cleared for NHS use via Cancer Drugs FundNICE has recommended the use of AstraZeneca and Daiichi Sankyo’s Enhertu in draft guidance, the first time the Share XEnhertu cleared for NHS use via Cancer Drugs Fundhttps://pharmaphorum.com/news/enhertu-cleared-for-nhs-use-via-cancer-drugs-fund/
Daiichi Sankyo announces UK digital AF collaborationDaiichi Sankyo has announced a collaboration with three technology partners to improve timely detection and diagnosis of atrial Share XDaiichi Sankyo announces UK digital AF collaborationhttps://pharmaphorum.com/news/daiichi-sankyo-announces-uk-digital-af-collaboration/
NICE backs AZ’s Calquence for new use in leukaemiaAstraZeneca’s BTK inhibitor Calquence has become the first targeted oral therapy to be backed by NICE for NHS Share XNICE backs AZ’s Calquence for new use in leukaemiahttps://pharmaphorum.com/news/nice-backs-azs-calquence-for-new-use-in-leukaemia/
AZ/Daiichi Sankyo’s partnership makes progress in lung cancerAstraZeneca and Daiichi Sankyo have announced data from two drugs in lung cancer, which they are developing as Share XAZ/Daiichi Sankyo’s partnership makes progress in lung cancerhttps://pharmaphorum.com/news/az-daiichi-sankyos-partnership-makes-progress-in-lung-cancer/
AZ/Daiichi Sankyo’s Enhertu gets second US cancer indicationAstraZeneca and Daiichi Sankyo’s Enhertu cancer drug has picked up a second indication, in patients who have stomach Share XAZ/Daiichi Sankyo’s Enhertu gets second US cancer indicationhttps://pharmaphorum.com/news/az-daiichi-sankyos-enhertu-gets-second-us-cancer-indication/
MacroGenics’ HER2 breast cancer drug Margenza approved in USMacroGenics’ HER2-targeted breast cancer drug Margenza has been approved by the FDA, challenging several recently approved drugs with Share XMacroGenics’ HER2 breast cancer drug Margenza approved in UShttps://pharmaphorum.com/news/macrogenics-her2-breast-cancer-drug-margenza-approved-in-us/
Daiichi Sankyo, AZ close on EU approval of Enhertu for breast cancerDaiichi Sankyo and AstraZeneca could be just weeks away from an EU approval for their antibody-drug conjugate (ADC) Share XDaiichi Sankyo, AZ close on EU approval of Enhertu for breast cancerhttps://pharmaphorum.com/news/daiichi-sankyo-az-close-on-eu-approval-of-enhertu-for-breast-cancer/
Scotland says no to Daiichi Sankyo’s cholesterol drug NilemdoThe Scottish Medicines Consortium (SMC) has rejected Daiichi Sankyo’s new cholesterol-lowering drug Nilemdo for use by NHS Scotland, Share XScotland says no to Daiichi Sankyo’s cholesterol drug Nilemdohttps://pharmaphorum.com/news/scotland-says-no-to-daiichi-sankyos-cholesterol-drug-nilemdo/
Gilead pays $21bn for Immunomedics ahead of breast cancer trial readoutGilead has made another big oncology acquisition, paying $21 billion for US biotech Immunomedics and its potential cancer Share XGilead pays $21bn for Immunomedics ahead of breast cancer trial readouthttps://pharmaphorum.com/news/gilead-pays-21bn-for-immunomedics-ahead-of-breast-cancer-trial-readout/
